Ren K, Hamdy H, Meyiah A, Elkord E
Front Immunol. 2024; 15():1501613.
PMID: 39660130
PMC: 11628531.
DOI: 10.3389/fimmu.2024.1501613.
Derakhshandeh R, Zhu Y, Li J, Hester D, Younis R, Koka R
Int J Mol Sci. 2024; 25(22).
PMID: 39596374
PMC: 11595306.
DOI: 10.3390/ijms252212309.
Leitner J, Aigner-Radakovics K, Steinberger P
FASEB J. 2024; 38(22):e70190.
PMID: 39560030
PMC: 11698013.
DOI: 10.1096/fj.202401639R.
Rigopoulos C, Georgakopoulos-Soares I, Zaravinos A
J Pers Med. 2024; 14(7).
PMID: 39064019
PMC: 11278172.
DOI: 10.3390/jpm14070765.
Theune W, Chen J, Theune E, Ye X, Menoret A, Vella A
Front Immunol. 2024; 15:1408710.
PMID: 38947320
PMC: 11211274.
DOI: 10.3389/fimmu.2024.1408710.
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.
Hamid O, Lewis K, Weise A, McKean M, Papadopoulos K, Crown J
J Clin Oncol. 2024; 42(24):2928-2938.
PMID: 38900987
PMC: 11328921.
DOI: 10.1200/JCO.23.02172.
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations.
Butterfield L, Najjar Y
Nat Rev Immunol. 2023; 24(6):399-416.
PMID: 38057451
PMC: 11460566.
DOI: 10.1038/s41577-023-00973-8.
Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice.
Daei Sorkhabi A, Komijani E, Sarkesh A, Shadbad P, Aghebati-Maleki A, Aghebati-Maleki L
Cell Commun Signal. 2023; 21(1):321.
PMID: 37946301
PMC: 10634124.
DOI: 10.1186/s12964-023-01289-9.
LAG-3 as the third checkpoint inhibitor.
Aggarwal V, Workman C, Vignali D
Nat Immunol. 2023; 24(9):1415-1422.
PMID: 37488429
PMC: 11144386.
DOI: 10.1038/s41590-023-01569-z.
Immunotherapy: an emerging modality to checkmate brain metastasis.
Ahmad A, Khan P, Rehman A, Batra S, Nasser M
Mol Cancer. 2023; 22(1):111.
PMID: 37454123
PMC: 10349473.
DOI: 10.1186/s12943-023-01818-7.
Tackling of Immunorefractory Tumors by Targeting Alternative Immune Checkpoints.
Dulal D, Boring A, Terrero D, Johnson T, Tiwari A, Raman D
Cancers (Basel). 2023; 15(10).
PMID: 37345111
PMC: 10216651.
DOI: 10.3390/cancers15102774.
Potential Immunotherapy Targets for Liver-Directed Therapies, and the Current Scope of Immunotherapeutics for Liver-Related Malignancies.
Charles J, Vrionis A, Mansur A, Mathias T, Shaikh J, Ciner A
Cancers (Basel). 2023; 15(9).
PMID: 37174089
PMC: 10177356.
DOI: 10.3390/cancers15092624.
Diversity of immune checkpoints in cancer immunotherapy.
Guo Z, Zhang R, Yang A, Zheng G
Front Immunol. 2023; 14:1121285.
PMID: 36960057
PMC: 10027905.
DOI: 10.3389/fimmu.2023.1121285.
TIGIT signaling and its influence on T cell metabolism and immune cell function in the tumor microenvironment.
Jantz-Naeem N, Bottcher-Loschinski R, Borucki K, Mitchell-Flack M, Bottcher M, Schraven B
Front Oncol. 2023; 13:1060112.
PMID: 36874131
PMC: 9982004.
DOI: 10.3389/fonc.2023.1060112.
In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways.
Abdeladhim M, Karnell J, Rieder S
Front Immunol. 2023; 13:1033705.
PMID: 36591244
PMC: 9799097.
DOI: 10.3389/fimmu.2022.1033705.
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy.
Botticelli A, Pomati G, Cirillo A, Scagnoli S, Pisegna S, Chiavassa A
Front Immunol. 2022; 13:974087.
PMID: 36405727
PMC: 9671166.
DOI: 10.3389/fimmu.2022.974087.
Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy.
Yu L, Sun M, Zhang Q, Zhou Q, Wang Y
Front Immunol. 2022; 13:982026.
PMID: 36159789
PMC: 9498063.
DOI: 10.3389/fimmu.2022.982026.
Epitope Mapping of Therapeutic Antibodies Targeting Human LAG3.
Agnihotri P, Mishra A, Agarwal P, Vignali K, Workman C, Vignali D
J Immunol. 2022; 209(8):1586-1594.
PMID: 36104110
PMC: 9696730.
DOI: 10.4049/jimmunol.2200309.
Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab.
Thudium K, Selby M, Zorn J, Rak G, Wang X, Bunch R
Cancer Immunol Res. 2022; 10(10):1175-1189.
PMID: 35981087
PMC: 9530649.
DOI: 10.1158/2326-6066.CIR-22-0057.
Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies.
Park K, Veena M, Shin D
Front Cell Dev Biol. 2022; 10:830208.
PMID: 35345849
PMC: 8957227.
DOI: 10.3389/fcell.2022.830208.
